{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:16:42Z","timestamp":1772151402374,"version":"3.50.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Methotrexate is a potentially toxic antifolate antineoplastic and immunosuppressive agent that is widely used in tumor chemotherapy and autoimmune diseases (such as psoriasis). It is the cornerstone therapy for immune-mediated disorders worldwide. However, low-dose methotrexate therapy for psoriasis rarely causes toxicity. Here, we report a case of a patient with psoriasis who was treated with low-dose methotrexate for the first time. The patient developed severe mucosal ulcers and myelosuppression, leading to impaired immunity and invasive pulmonary mucormycosis. After treatment, the patient recovered and was discharged. It demonstrates that even low-dose methotrexate prescribed for psoriasis can induce severe toxicity. The case highlights the potential for low-dose methotrexate toxicity, suggesting that genetic polymorphisms may increase the risk of toxicity. The influence of genetic polymorphisms on methotrexate metabolism is highly variable. It is important to strengthen early monitoring in clinical practice, improve toxicity prediction models, and establish risk assessment systems for toxic drugs.<\/jats:p>","DOI":"10.3389\/fphar.2025.1704810","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:38:01Z","timestamp":1763534281000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A rare case of low-dose methotrexate toxicity leading to skin and mucosal toxicity and invasive pulmonary mucormycosis: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Lin","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinggong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/leu.2009.67","article-title":"Reduced folate carrier and methylenetetrahydrofolate reductase gene polymorphisms: associations with clinical outcome in childhood acute lymphoblastic leukemia","volume":"23","author":"Ashton","year":"2009","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2165\/00003088-199630030-00002","article-title":"Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis","volume":"30","author":"Bannwarth","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.3390\/ijms20205023","article-title":"Methotrexate an old drug with new tricks","volume":"20","author":"Bedoui","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1182\/blood.v93.5.1643.405k06_1643_1650","article-title":"Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation","volume":"93","author":"Belkov","year":"1999","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.immuni.2023.04.001","article-title":"Methotrexate suppresses psoriatic skin inflammation by inhibiting muropeptide transporter SLC46A2 activity","volume":"56","author":"Bharadwaj","year":"2023","journal-title":"Immunity"},{"key":"B6","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bcp.16096","article-title":"Navigating methotrexate toxicity: examining the therapeutic roles of folinic acid and glucarpidase","volume":"91","author":"Chan","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1136\/ard.2004.033399","article-title":"Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study","volume":"64","author":"Dervieux","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res. Hob."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41590-025-02136-4","article-title":"Systemic inflammation impairs myelopoiesis and interferon type I responses in humans","volume":"26","author":"Keramati","year":"2025","journal-title":"Nat. Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"E423","DOI":"10.1503\/cmaj.181054","article-title":"Low-dose methotrexate toxicity","volume":"191","author":"Kevin","year":"2019","journal-title":"Can. Med. Assoc. J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.autrev.2014.08.027","article-title":"Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients","volume":"13","author":"Kivity","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.3390\/ijms21103483","article-title":"Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers","volume":"21","author":"Ko\u017ami\u0144ski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"107589","DOI":"10.1016\/j.phrs.2025.107589","article-title":"Unraveling the pathogenesis of bone marrow hematopoietic injury and the therapeutic potential of natural products","volume":"212","author":"Long","year":"2025","journal-title":"Pharmacol. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/cpt.1008","article-title":"Endogenous metabolites-mediated communication between OAT1\/OAT3 and OATP1B1 may explain the association between SLCO1B1 SNPs and methotrexate toxicity","volume":"104","author":"Martinez","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"9695","DOI":"10.1038\/s41598-024-60334-w","article-title":"Genetic polymorphisms and clinical parameters associated with renal toxicity in Thai hematologic malignancy patients receiving high dose methotrexate","volume":"14","author":"Pitakkitnukun","year":"2024","journal-title":"Sci. Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s12026-014-8564-6","article-title":"Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?","volume":"60","author":"Rom\u00e3o","year":"2014","journal-title":"Immunol. Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1365-2141.2009.07765.x","article-title":"Advances in individual prediction of methotrexate toxicity: a review","volume":"146","author":"Schmiegelow","year":"2009","journal-title":"Br. J. Haematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"757464","DOI":"10.3389\/fphar.2021.757464","article-title":"The role of genetic polymorphisms in high-dose methotrexate toxicity and response in hematological malignancies: a systematic review and meta-analysis","volume":"12","author":"Song","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"116617","DOI":"10.1016\/j.bcp.2024.116617","article-title":"Evaluation of UCP1162, a potent propargyl-linked inhibitor of dihydrofolate reductase with potential application to cancer and autoimmune disease","volume":"230","author":"Tezgin","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"184117893","DOI":"10.1016\/j.biopha.2025.117893","article-title":"Thiopurine S-methyltransferase \u2013 an important intersection of drug-drug interactions in thiopurine treatment","volume":"184","author":"Urban\u010di\u010d","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/apt.17719","article-title":"Therapeutic drug monitoring of methotrexate in patients with crohn's disease","volume":"58","author":"van de Meeberg","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40262-024-01452-6","article-title":"Population pharmacokinetic and toxicity analysis of high-dose methotrexate in patients with central nervous system lymphoma","volume":"64","author":"Yin","year":"2025","journal-title":"Clin. Pharmacokinet."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1704810\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:38:04Z","timestamp":1763534284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1704810\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":24,"alternative-id":["10.3389\/fphar.2025.1704810"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1704810","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"article-number":"1704810"}}